| GERON ALERT: Bragar Eagel & Squire, P.C. is Investigating Geron Corporation on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm |
NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Geron Corporation (NASDAQ: GERN) on behalf of long-term stockholders following a class action complaint that was filed against Geron on March 14, 2025 with a Class Period from February 28, 2024 to February 25, 2025. Our investigation concerns whether the board of directors of Geron have breached their fiduciary duties to the company. |
globenewswire.com |
2025-05-16 01:00:00 |
Czytaj oryginał (ang.) |
| Geron Corporation Class Action: Levi & Korsinsky Reminds Geron Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 12, 2025 - GERN |
NEW YORK, NY / ACCESS Newswire / May 12, 2025 / If you suffered a loss on your Geron Corporation (NASDAQ:GERN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/geron-corporation-lawsuit-submission-form?prid=148178&wire=1 or contact Joseph E. Levi, Esq. |
accessnewswire.com |
2025-05-12 22:30:00 |
Czytaj oryginał (ang.) |
| Geron Corporation Investors: Please contact the Portnoy Law Firm to recover your losses. May 12 2025 Deadline to file Lead Plaintiff Motion. |
LOS ANGELES, May 12, 2025 (GLOBE NEWSWIRE) -- Investors can contact the law firm at no cost to learn more about recovering their losses |
globenewswire.com |
2025-05-12 22:10:00 |
Czytaj oryginał (ang.) |
| Geron Corporation Sued for Securities Law Violations - Contact Levi & Korsinsky Before May 12, 2025 to Discuss Your Rights - GERN |
NEW YORK, NY / ACCESS Newswire / May 12, 2025 / If you suffered a loss on your Geron Corporation (NASDAQ:GERN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/geron-corporation-lawsuit-submission-form?prid=148118&wire=1 or contact Joseph E. Levi, Esq. |
accessnewswire.com |
2025-05-12 18:00:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Geron Corporation and Certain Officers - GERN |
NEW YORK , May 12, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Geron Corporation ("Geron" or the "Company") (NASDAQ: GERN) and certain officers. The class action, filed in the United States District Court for the Northern District of California, and docketed under 25-cv-02563, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Geron securities between February 28, 2024 and February 25, 2025, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 ("Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials. |
prnewswire.com |
2025-05-12 17:39:00 |
Czytaj oryginał (ang.) |
| The Gross Law Firm Notifies Shareholders of Geron Corporation(GERN) of a Class Action Lawsuit and an Upcoming Deadline |
NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Geron Corporation (NASDAQ: GERN). |
globenewswire.com |
2025-05-12 17:12:00 |
Czytaj oryginał (ang.) |
| Geron Corporation Class Action: Levi & Korsinsky Reminds Geron Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 12, 2025 - GERN |
NEW YORK, NY / ACCESS Newswire / May 12, 2025 / If you suffered a loss on your Geron Corporation (NASDAQ:GERN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/geron-corporation-lawsuit-submission-form?prid=148086&wire=1 or contact Joseph E. Levi, Esq. |
accessnewswire.com |
2025-05-12 14:15:00 |
Czytaj oryginał (ang.) |
| GERN Investors are Reminded of an Opportunity to Lead Geron Corporation Securities Fraud Lawsuit with the Schall Law Firm |
LOS ANGELES , May 12, 2025 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Geron Corporation ("Geron" or "the Company") (NASDAQ: GERN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between June 7, 2024 and February 25, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before May 12, 2025. |
prnewswire.com |
2025-05-12 13:54:00 |
Czytaj oryginał (ang.) |
| Geron Corporation Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before May 12, 2025 to Discuss Your Rights - GERN |
NEW YORK, NY / ACCESS Newswire / May 12, 2025 / If you suffered a loss on your Geron Corporation (NASDAQ:GERN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/geron-corporation-lawsuit-submission-form?prid=148008&wire=1 or contact Joseph E. Levi, Esq. |
accessnewswire.com |
2025-05-12 11:25:00 |
Czytaj oryginał (ang.) |
| FINAL REMINDER GERN DEADLINE: Bronstein, Gewirtz & Grossman LLC Alerts Geron Corporation Investors to Participate in the Class Action Lawsuit |
NEW YORK CITY, NY / ACCESS Newswire / May 12, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Geron Corporation ("Geron" or "the Company") (NASDAQ:GERN) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Geron securities between February 28, 2024, and February 25, 2025, both dates inclusive (the "Class Period"). |
accessnewswire.com |
2025-05-12 11:00:00 |
Czytaj oryginał (ang.) |
| The Gross Law Firm Reminds Geron Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 12, 2025 - GERN |
NEW YORK , May 12, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Geron Corporation (NASDAQ: GERN). Shareholders who purchased shares of GERN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. |
prnewswire.com |
2025-05-12 09:45:00 |
Czytaj oryginał (ang.) |
| Levi & Korsinsky Reminds Geron Corporation Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 12, 2025 - GERN |
NEW YORK, NY / ACCESS Newswire / May 11, 2025 / If you suffered a loss on your Geron Corporation (NASDAQ:GERN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/geron-corporation-lawsuit-submission-form?prid=147960&wire=1 or contact Joseph E. Levi, Esq. |
accessnewswire.com |
2025-05-11 22:35:00 |
Czytaj oryginał (ang.) |
| GERN DEADLINE NOTICE: ROSEN, A TOP RANKED LAW FIRM, Encourages Geron Corporation Investors with Losses in Excess of $100K to Secure Counsel Before Important May 12 Deadline in Securities Class Action - GERN |
NEW YORK CITY, NY / ACCESS Newswire / May 11, 2025 / WHY: New York, N.Y., May 11, 2025. |
accessnewswire.com |
2025-05-11 22:11:00 |
Czytaj oryginał (ang.) |
| Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of May 12, 2025 in Geron Lawsuit - GERN |
NEW YORK, NY / ACCESS Newswire / May 11, 2025 / If you suffered a loss on your Geron Corporation (NASDAQ:GERN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/geron-corporation-lawsuit-submission-form?prid=147940&wire=1 or contact Joseph E. Levi, Esq. |
accessnewswire.com |
2025-05-11 17:00:00 |
Czytaj oryginał (ang.) |
| GERN Deadline in 1 Day: Kessler Topaz Meltzer & Check, LLP Reminds Geron Corporation (GERN) Investors of Filing Deadline in Class Action Lawsuit |
RADNOR, PA / ACCESS Newswire / May 11, 2025 / The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that securities class action lawsuits have been filed against Geron Corporation ("Geron") (NASDAQ:GERN) on behalf of those who purchased or otherwise acquired Geron securities between February 28, 2024, and February 25, 2025, inclusive (the "Class Period"). The lead plaintiff deadline is May 12, 2025. |
accessnewswire.com |
2025-05-11 16:00:00 |
Czytaj oryginał (ang.) |
| Levi & Korsinsky Notifies Geron Corporation Investors of a Class Action Lawsuit and Upcoming Deadline - GERN |
NEW YORK, NY / ACCESS Newswire / May 11, 2025 / If you suffered a loss on your Geron Corporation (NASDAQ:GERN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/geron-corporation-lawsuit-submission-form?prid=147921&wire=1 or contact Joseph E. Levi, Esq. |
accessnewswire.com |
2025-05-11 13:27:00 |
Czytaj oryginał (ang.) |
| Faruqi & Faruqi Reminds Geron Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 12, 2025 - GERN |
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Geron To Contact Him Directly To Discuss Their Options |
globenewswire.com |
2025-05-11 12:17:00 |
Czytaj oryginał (ang.) |
| Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of May 12, 2025 in Geron Corporation Lawsuit - GERN |
NEW YORK, NY / ACCESS Newswire / May 11, 2025 / If you suffered a loss on your Geron Corporation (NASDAQ:GERN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/geron-corporation-lawsuit-submission-form?prid=147904&wire=1 or contact Joseph E. Levi, Esq. |
accessnewswire.com |
2025-05-11 11:13:00 |
Czytaj oryginał (ang.) |
| FINAL GERN DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Geron Corporation Investors to Join the Class Action Lawsuit |
NEW YORK CITY, NY / ACCESS Newswire / May 11, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Geron Corporation ("Geron" or "the Company") (NASDAQ:GERN) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Geron securities between February 28, 2024, and February 25, 2025, both dates inclusive (the "Class Period"). |
accessnewswire.com |
2025-05-11 11:00:00 |
Czytaj oryginał (ang.) |
| Geron Corporation Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before May 12, 2025 to Discuss Your Rights - GERN |
NEW YORK, NY / ACCESS Newswire / May 10, 2025 / If you suffered a loss on your Geron Corporation (NASDAQ:GERN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/geron-corporation-lawsuit-submission-form?prid=147865&wire=1 or contact Joseph E. Levi, Esq. |
accessnewswire.com |
2025-05-10 22:01:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Geron Corporation - GERN |
NEW YORK , Feb. 26, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Geron Corporation ("Geron" or the "Company") (NASDAQ: GERN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
prnewswire.com |
2025-02-26 22:28:00 |
Czytaj oryginał (ang.) |
| Why Geron Stock Is Plummeting Today |
Geron (GERN -31.43%) stock is getting crushed in Wednesday's trading. The company's share price was down 31.7% as of 3:50 p.m. |
fool.com |
2025-02-26 18:02:00 |
Czytaj oryginał (ang.) |
| Geron: Rytelo's Market Share Concerns Justified As 3L Dominates Early Sales |
Geron Corporation's stock dropped 50% before its Q4 2024 earnings report, with Rytelo's revenue close to projections but new patients starts flat. Rytelo's market share in second-line LR-MDS is lower than expected due to competition from Bristol Myers Squibb's luspatercept, impacting peak sales estimates. Financial health remains solid with a strong current ratio and cash runway extending into mid-2027, supported by recent funding deals. |
seekingalpha.com |
2025-02-26 14:12:11 |
Czytaj oryginał (ang.) |
| Geron Corporation (GERN) Q4 2024 Earnings Call Transcript |
Geron Corporation (NASDAQ:GERN ) Q4 2024 Earnings Conference Call February 26, 2025 8:00 AM ET Company Participants Aron Feingold - VP of IR and Corporate Communications John Scarlett - Chairman and CEO Michelle Robertson - EVP and CFO Jim Ziegler - EVP and CCO Joseph Eid - EVP, R&D Faye Feller - EVP and CMO Conference Call Participants Peter Lawson - Barclays Tara Bancroft - TD Cowen Faisal Khurshid - Leerink Partners Greg Harrison - Scotiabank Stephen Willey - Stifel Emily Bodnar - H.C. Wainwright Kalpit Patel - B. |
seekingalpha.com |
2025-02-26 13:31:07 |
Czytaj oryginał (ang.) |
| Geron (GERN) Reports Q4 Loss, Tops Revenue Estimates |
Geron (GERN) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to loss of $0.09 per share a year ago. |
zacks.com |
2025-02-26 11:40:30 |
Czytaj oryginał (ang.) |
| Geron Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights |
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today reported financial results for the fourth quarter and full year 2024 and recent business highlights. "2024 was a terrific year for Geron and for RYTELO, our first-in-class telomerase inhibitor, which we believe represents a highly differentiated treatment with blockbuster potential in the high unmet need, lower-. |
businesswire.com |
2025-02-26 09:30:00 |
Czytaj oryginał (ang.) |
| 3 Biotech/Healthcare Names Under $10 I Am Buying Now |
Today, I am highlighting three biotech/healthcare stocks that currently trade under $10 a share after some recent weakness. ! am slowly accumulating each of these names on these dips both straight equity purchases and covered call orders. All have had some recent positive despite the action in the shares and have good longer-term prospects. |
seekingalpha.com |
2025-02-21 18:21:52 |
Czytaj oryginał (ang.) |
| Geron to Participate at Upcoming Investor Conferences in March 2025 |
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company, today announced that members of the management team are scheduled to participate in fireside chats at the following investor conferences: TD Cowen 45th Annual Health Care Conference Monday, March 3rd at 3:10pm ET (Boston, MA) Leerink Global Healthcare Conference Monday, March 10th 3:00pm ET (Miami, FL) Barclays 27th Annual Global Healthcare Conference Tuesday, March 11th 10:30am. |
businesswire.com |
2025-02-21 11:00:00 |
Czytaj oryginał (ang.) |
| Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted equity awards covering an aggregate of 180,000 shares of its common stock, consisting of stock options to purchase an aggregate of 120,000 shares of common stock and restricted stock units (“RSUs”) representing an aggregate of 60,000 shares of common stock, to two newly hired employees as an inducement material to their acceptance of employment. |
businesswire.com |
2025-02-19 18:15:00 |
Czytaj oryginał (ang.) |
| Geron Corporation: Lackluster Share Price Performance Despite Reasonable Drug Launch |
GERN's Rytelo, approved in mid-2024, shows promising initial sales, with Q3'24 net revenues at $28.2M, and preliminary Q4'24 net revenues of $45M-$46M. Despite some market exclusivity concerns, GERN still has many years of sales ahead unencumbered by generic competition. EU approval of Rytelo for lower-risk myelodysplastic syndromes seems likely in H1'25, providing a near-term catalyst beyond updates on sales. |
seekingalpha.com |
2025-02-03 12:46:06 |
Czytaj oryginał (ang.) |
| Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted equity awards covering an aggregate of 312,000 shares of its common stock, consisting of stock options to purchase an aggregate of 208,000 shares of common stock and restricted stock units (“RSUs”) representing an aggregate of 104,000 shares of common stock, to three newly hired employees as an inducement material to their acceptance of employm. |
businesswire.com |
2025-01-21 18:30:00 |
Czytaj oryginał (ang.) |
| Geron: Positive IMpactMF Trial Could Possibly Lead To Doubling Of RYTELO Sales |
Geron Corporation's RYTELO received FDA approval for Low-Risk Myelodysplastic Syndrome and is awaiting European Medicines Agency approval as well, which might help to boost sales. Geron reported $28.2 million in the first full quarter of sales of RYTELO, with projections of $45-$46 million set for Q4 2024. Geron is conducting a Phase 3 study for RYTELO targeting JAK inhibitor relapsed/refractory Myelofibrosis patients, with interim results expected by early 2026 and final results early 2027. |
seekingalpha.com |
2025-01-16 15:46:23 |
Czytaj oryginał (ang.) |
| Geron Stock Rallies More Than 60% in a Year: Here's Why |
FDA's approval of GERN's Rytelo (imetelstat) for treating low- to intermediate-1 risk MDS drives the stock 61.1% higher in the past year. |
zacks.com |
2025-01-08 13:40:31 |
Czytaj oryginał (ang.) |
| Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted non-statutory stock options to purchase an aggregate of 72,000 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company. The stock options were granted on December 18, 2024, at an exercise price $3.77 per share, which is equal to the closing price of Geron common stock o. |
businesswire.com |
2024-12-19 18:30:00 |
Czytaj oryginał (ang.) |
| Geron Announces Positive CHMP Opinion for RYTELO™ (imetelstat) for the Treatment of Adults with Transfusion-Dependent Anemia due to Lower-Risk MDS |
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the approval of RYTELO (imetelstat) for the treatment of adult patients with transfusion-dependent (TD) anemia due to very low, low or intermediate risk myel. |
businesswire.com |
2024-12-13 08:36:00 |
Czytaj oryginał (ang.) |
| Geron to Participate in the 7th Annual Evercore ISI HealthCONx Conference |
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company, today announced that members of the management team are scheduled to participate in a fireside chat at the 7th Annual Evercore ISI HealthCONx Conference, in Coral Gables, Florida on Wednesday, December 4, 2024, at 8:20 a.m. ET. A webcast of the fireside chat will be available through the Investors and Media section of Geron's website under Events following the presentation. The. |
businesswire.com |
2024-11-27 11:00:00 |
Czytaj oryginał (ang.) |
| Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted non-statutory stock options to purchase an aggregate of 1,017,000 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company. The stock options were granted on November 20, 2024, at an exercise price $3.99 per share, which is equal to the closing price of Geron common stoc. |
businesswire.com |
2024-11-21 18:30:00 |
Czytaj oryginał (ang.) |
| Geron: A Strong Launch And Financial Deals Make It Attractive |
Geron exceeded expectations with $28.2mn in Q1 revenue, surpassing analyst estimates and showcasing strong physician feedback and market potential for imetelstat. Analysts are bullish, with H.C. Wainwright, Leerink, and Goldman Sachs projecting significant sales growth and maintaining high price targets for Geron. Favorable funding deals with Royalty Pharma and Pharmakon Advisors provide $375mn, enhancing Geron's financial stability and supporting future commercialization efforts. |
seekingalpha.com |
2024-11-21 17:05:01 |
Czytaj oryginał (ang.) |
| Geron Corporation Announces Appointment of Joseph Eid, M.D. as Executive Vice President, Research and Development |
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced the appointment of Joseph Eid, M.D. as Executive Vice President, Research and Development, effective today, November 11, 2024. In this role, Dr. Eid will lead our Research and Development organization comprised of medical, clinical, and safety/pharmacovigilance teams and be responsible for driving inno. |
businesswire.com |
2024-11-11 18:30:00 |
Czytaj oryginał (ang.) |
| Geron to Participate in the Stifel 2024 Healthcare Conference |
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company, today announced members of the management team are scheduled to participate in a fireside chat at the Stifel 2024 Healthcare Conference, in New York City, on Monday, November 18th, 2024, at 1:50pm ET. A webcast of the fireside chat will be available through the Investors and Media section of Geron's website under Events following the presentation. The webcast will be archived an. |
businesswire.com |
2024-11-11 11:00:00 |
Czytaj oryginał (ang.) |
| Geron: A Post Earnings And Funding Announcement Assessment |
Geron Corporation's imetelstat, now branded as Rytelo, was finally approved by the FDA in June for treating lower risk myelodysplastic syndromes and has shown solid initial sales traction. The company just reported third quarter results and announced a new financing arrangement. Analyst firms are positive on the company's prospects. An updated analysis of Geron Corporation follows in the paragraphs below. |
seekingalpha.com |
2024-11-07 15:01:49 |
Czytaj oryginał (ang.) |
| Geron Corporation (GERN) Q3 2024 Earnings Call Transcript |
Geron Corporation (NASDAQ:GERN ) Q3 2024 Results Conference Call November 7, 2024 8:00 AM ET Company Participants Aron Feingold - Vice President of IR and Corporate Communication John Scarlett - Chairman and CEO Jim Ziegler - EVP and CCO Michelle Robertson - EVP and CFO Faye Feller - EVP, CMO Andrew Grethlein - EVP, COO Conference Call Participants Tara Bancroft - T. D. Cowen Faisal Khurshid - Leerink Partners Corinne Johnson - Goldman Sachs Carter Gould - Barclays Emily Bodnar - H.C. |
seekingalpha.com |
2024-11-07 13:20:30 |
Czytaj oryginał (ang.) |
| Geron (GERN) Reports Q3 Loss, Tops Revenue Estimates |
Geron (GERN) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to loss of $0.08 per share a year ago. |
zacks.com |
2024-11-07 11:21:13 |
Czytaj oryginał (ang.) |
| Royalty Pharma to Acquire Royalty Interest in Geron's RYTELO for $125 Million |
NEW YORK, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will acquire a synthetic royalty on U.S. sales of Geron Corporation's (Nasdaq: GERN) RYTELO for $125 million in cash upfront. |
globenewswire.com |
2024-11-07 09:10:00 |
Czytaj oryginał (ang.) |
| Geron Corporation Announces Up to $375 Million in Funding with Royalty Pharma and Pharmakon Advisors |
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced up to $375 million in synthetic royalty and debt financings with Royalty Pharma and investment funds managed by Pharmakon Advisors, LP, of which $250 million in cash was provided at closing and another $125 million in debt is available. The transactions are comprised of a $125 million synthetic royalty. |
businesswire.com |
2024-11-07 09:01:00 |
Czytaj oryginał (ang.) |
| Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted non-statutory stock options to purchase an aggregate of 680,220 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company. The stock options were granted on October 16, 2024, at an exercise price of $4.17 per share, which is equal to the closing price of Geron common stoc. |
businesswire.com |
2024-10-17 20:30:00 |
Czytaj oryginał (ang.) |
| Geron to Announce Third Quarter 2024 Financial Results on November 7, 2024 |
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company, today announced that it will release its third quarter 2024 financial results and business highlights before the market opens on Thursday, November 7, 2024 via press release, which will be available on the Company's website at www.geron.com/investors. Geron will host a conference call to discuss the financial results as well as business highlights at 8:00 a.m. ET the same day. A. |
businesswire.com |
2024-10-15 20:30:00 |
Czytaj oryginał (ang.) |
| Geron: Derisked And Highly Attractive After Approval |
Geron's imetelstat (Rytelo) received FDA approval for MDS, marking a significant milestone despite past setbacks and negative comments from the FDA. Imetelstat, a telomerase inhibitor, shows promise in treating MDS and MF, with significant clinical trial results and manageable adverse events. Geron's financials are strong with a $2.8bn market cap and cash runway until 2026, positioning it well for future growth. |
seekingalpha.com |
2024-09-23 21:17:40 |
Czytaj oryginał (ang.) |
| Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted non-statutory stock options to purchase an aggregate of 500,220 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company. The stock options were granted on September 18, 2024, at an exercise price of $4.52 per share, which is equal to the closing price of Geron common st. |
businesswire.com |
2024-09-19 20:30:00 |
Czytaj oryginał (ang.) |
| Geron Corporation Announces Appointment of Jim Ziegler as Chief Commercial Officer |
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, announced the appointment of Jim Ziegler as Executive Vice President, Chief Commercial Officer, effective today, September 9, 2024. In this role, Mr. Ziegler will spearhead Geron's global commercial strategy and operations, lead the commercial organization and be responsible for driving growth of RYTELO™. Mr. Ziegler. |
businesswire.com |
2024-09-09 20:15:00 |
Czytaj oryginał (ang.) |
| Geron (GERN) Reports Q2 Loss, Tops Revenue Estimates |
Geron (GERN) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to loss of $0.09 per share a year ago. |
zacks.com |
2024-08-08 13:17:15 |
Czytaj oryginał (ang.) |
| Geron Announces Updated NCCN Guidelines® Recommending RYTELO™ (imetelstat) for the Treatment of Symptomatic Anemia in Patients with Lower-Risk MDS |
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that the National Comprehensive Cancer Network (NCCN) has updated its Clinical Practice Guidelines in Oncology (NCCN Guidelines) for the treatment of Myelodysplastic Syndromes (MDS) to recommend RYTELO™ (imetelstat) as a Category 1 and 2A treatment of symptomatic anemia in patients with lower-risk MDS. |
businesswire.com |
2024-07-26 11:30:00 |
Czytaj oryginał (ang.) |
| Geron to Announce Second Quarter 2024 Financial Results on August 8, 2024 |
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company, today announced that it will release its second quarter 2024 financial results and business highlights before the market opens on Thursday, August 8, 2024 via press release, which will be available on the Company's website at www.geron.com/investors. Geron will host a conference call to discuss the financial results as well as business highlights at 8:00 a.m. ET the same day. A. |
businesswire.com |
2024-07-18 20:30:00 |
Czytaj oryginał (ang.) |